InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

It seems like it was only 2 months ago that Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) were approved ...

The pupillary dilation caused by phenylephrine and tropicamide can be reversed with dapiprazole hydrocloride (Rev-Eyes™, Storz Ophthalmic, a division of Bausch & Lomb, Rochester, NY) Dapiprazole ...

ophthalmic pharmaceuticals, over-the-counter products, and surgical devices. As a significant player in the global eye health sector, Bausch + Lomb Corporation (NYSE:BLCO) has a presence in nearly ...

Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday. The company’s ...

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX ... Although there is currently no cure for glaucoma, early intervention – including prescription eye drops – can help slow the disease’s ...